Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles

Clinical Pharmacokinetics

Volumn 47, Issue 4, 2008, Pages 245-259

  Peters, Sheila Annie ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

VERAPAMIL;

ARTICLE; BILIARY EXCRETION; COMPUTER PROGRAM; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ISOLATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; FIRST PASS EFFECT; HUMAN; INTESTINE WALL; LIVER METABOLISM; NONHUMAN; PARAMETER; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RELIABILITY; SIMULATION; STOMACH EMPTYING; TISSUE DISTRIBUTION; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PHARMACOKINETICS; SPECIES SPECIFICITY; VERAPAMIL;

EID: 40549096396     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847040-00003     Document Type: Article

References (49)

1. Zhang Y, Benet LZ. The gut as barrier to drug absorption: combined role of cytochrome P450 and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159-68
2. Christians U, Schmitz V, Haschke M. Functional interaction between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 2005; 1: 641-54
3. Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption: theoretical approach. Pharm Res 1999; 16: 225-31
4. Lee YJ, Chung SJ, Shim CK. Limited role of P-glycoprotein in the intestinal absorption of cyclosporin A. Biol Pharm Bull 2005; 28: 760-3
5. Saitoh H, Saikachi Y, Kobayashi M, et al. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Eur J Pharm Sci 2006; 28: 34-42
6. Cao X, Yu LX, Barbaciru C, et al. Permeability dominates the in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol Pharm 2004; 2: 329-40
7. Kwon H, Lionberger RA, Yu LX. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates. Mol Pharm 2004; 1: 455-65
8. Ogihara T, Kamiya M, Ozawa M, et al. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil and vinblastine. Drug Metab Pharmacokinet 2006; 21: 238-44
9. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26: 144-60
10. de Waziers I, Cugnenc PH, Yang CS, et al. Cytochrome P450 isozymes, epoxide hydrolase and glutathione transferasesin rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253: 387-94
11. Kaminsky LS. Small intestinal cytochromes P450. Toxicology 1992; 21: 407-22
12. Prueksaritanont T, Gorham LM, Hochman JH, et al. Comparative studies of drug-metabolising enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 1996; 24: 634-42
13. Kaji H, Kume T. Glucuronidation of 2-(4-chlorophenyl)-5-(2-furyl)-4- oxazoleacetic acid (TA-1801A) in humans: species differences in liver and intestinal microsomes. Drug Metab Pharmacokinet 2005; 20: 206-11
14. von Richter O, Burk O, Fromm MF, et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-83
15. Zhang Q, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochrome P-450. Drug Metab Dispos 1999; 27: 804-9
16. Lin JH, Chiba M, Baillie TA. Is the role of small intestine in first pass metabolism overemphasized? Pharmacol Rev 1999; 51: 135-58
17. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007; 117: 3583-92
18. van de Kerkhof EG, Ungell AL, Sjöberg AK, et al. Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with Ussing chamber preparations. Drug Metab Dispos 2006; 34: 1893-902
19. Lindell M, Karlsson MO, Lennernas H, et al. Variable expression of CYP and Pgp genes in the human small intestine. Eur J Clin Invest 2003; 33: 493-9
20. Hilgendorf C, Ahlin G, Seithel A, et al. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007; 35: 1333-40
21. von Richter O, Greiner B, Fromm MF, et al. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther 2001; 70: 217-27
22. Johnson BM, Chen W, Borchardt RT, et al. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum. J Pharmacol Exp Ther 2003; 305: 151-8
23. Glaeser H, Seigfried D, Hoffmann U, et al. Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin Pharmacol Ther 2004; 76: 230-8
24. Theil FP, Guentert TW, Haddad S, et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 2003; 138: 29-49
25. Christian L, Andreas R. Development and application of physiologically based pharmacokinetic modelling tools to support drug discovery. Chem Biodivers 2005; 2: 1462-86
26. Bernareggi A, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 1991; 19: 21-50
27. Peters SA. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 2008; 47: 261-75
28. Eichelbaum M, Mikus G, Vogelgesang B. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol 1984; 17: 453-8
29. Hanada K, Akimoto S, Mitsui K, et al. Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: role of plasma protein and tissue phosphatidylserine binding. Pharm Res 1998; 15: 1250-6
30. Avdeef A, Artursson P, Neuhoff S, et al. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa (flux) method. Eur J Pharm Sci 2005; 24: 333-49
31. Winiwarter S, Bonham NM, Ax F, et al. Correlation of human jejunal permeability (in vivo) of drugs with experimental and theoretically derived parameters: a multivariate data analysis approach. J Med Chem 1998; 41: 4939-49
32. Bhatti MM, Foster RT. Pharmacokinetics of the enantiomers of verapamil after the intravenous and oral administration of racemic verapamil in a rat model. Biopharm Drug Dispos 1997; 18: 387-96
33. Busse D, Templin S, Mikus G, et al. Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study. Eur J Clin Pharmacol 2006; 62: 613-9
34. McAllister RG, Kirsten EB. The pharmacology of verapamil: IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 1982; 31: 418-26
35. Björkman S, Stanski DR, Harashima H, et al. Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model. J Pharmacokinet Biopharm 1993; 21: 255-79
36. Peters SA, Hultin L. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat. J Pharmacokinet Pharmacodyn. Epub 2007 Oct 26
37. Brage R, Cortijo J, Esplungues J, et al. Effects of calcium channel blockers on gastric emptying and acid secretion of the rat in vivo. Br J Pharmacol 1986; 89: 627-33
38. Yavorsky RT, Hallgren SE, Blue PW. Effects of verapamil and diltiazem on gastric emptying in normal subjects. Dig Dis Sci 1991; 36: 1274-6
39. Krevsky B, Maurer AH, Niewiarowski T, et al. Effect of verapamil on human intestinal transit. Dig Dis Sci 1992; 37: 919-24
40. Tsimmerman IaS, Budnik IuB, Syman LN. The effect of calcium antagonists and beta-adrenoblockaders on disordered stomach functions in patients with duodenal peptic ulcer [in Russian]. Ter Arkh 1994; 66: 47-52
41. King CD, Rios GR, Green MD, et al. UDP-glucuronosyltransferases. Curr Drug Metab 2000; 1: 143-61
42. Fisher MB, Paine MF, Strelevitz TJ, et al. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 2001; 33: 273-97
43. Strassburg CP, Kneip S, Topp J, et al. Polymorphic gene regulation and inter-individual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 2000; 275: 36164-71
44. Sabolovic N, Heydel JM, Li X, et al. Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract. Biochim Biophys Acta 2004; 1675: 120-9
45. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 2004; 32: 314-20
46. Mistry M, Houston JB. Gluronidation in vitro and in vivo: comparison of intestinal and hepatic conjugation of morphine naloxone and buprenorphine. Drug Metab Dispos 1987; 15: 710-7
47. Kaminsky LS, Zhang Q-Y. The small intestine as a xenobiotic-metabolizing organ. Drug Metab Dispos 2003; 31: 1520-5
48. Wu C-Y, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492-7
49. Rodrigues AD, Winchell GA, Dobrinska MA. Use of in vitro drug metabolism data to evaluate drug-drug interactions in man: the need for quantitative databases. J Clin Pharmacol 2001 41: 368-373